Post Office Boosts Breast Cancer Stamp

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

WASHINGTON-Sales of the 40-cent Breast Cancer stamp generated $5.2 million for breast cancer research in the first 7 months following its release in July 1998. The US Postal Service plans a sales campaign tied to Mother’s Day, and it will promote the stamp in partnership with the Revlon Run/Walk for Women fund-raiser in Los Angeles and New York City

WASHINGTON—Sales of the 40-cent Breast Cancer stamp generated $5.2 million for breast cancer research in the first 7 months following its release in July 1998. The US Postal Service plans a sales campaign tied to Mother’s Day, and it will promote the stamp in partnership with the Revlon Run/Walk for Women fund-raiser in Los Angeles and New York City

Funds from the stamp’s sale above the regular cost of a first-class stamp, now 33 cents, go the National Institutes of Health (70%) and Department of Defense (30%) for breast cancer research

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content